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Abstract
Rationale: Implementation of intervention strategies to prevent
lung damage in early cystic fibrosis (CF) requires objective outcome
measures that capture and track lung disease.
Objectives: To define the utility of the Lung Clearance Index (LCI),
measured by multiple breath washout, as a means to track disease
progression in preschool children with CF.
Methods:Children with CF between the ages of 2.5 and 6 years with
a confirmed diagnosis of CF and age-matched healthy control
subjects were enrolled at three North American CF centers. Multiple
breath washout tests were performed at baseline, 1, 3, 6, and
12 months to mimic time points chosen in clinical care and
interventional trials; spirometry was also conducted. A generalized
linear mixed-effects model was used to distinguish LCI changes
associated with normal growth and development (i.e., healthy
children) from the progression of CF lung disease.
Measurements and Main Results: Data were collected on 156
participants with 800 LCI measurements. Although both LCI and
spirometry discriminated health fromdisease, only the LCI identified
significant deterioration of lung function in CF over time. The LCI
worsened during cough episodes and pulmonary exacerbations,
whereas similar symptoms in healthy children were not associated
with increased LCI values.
Conclusions: LCI is a useful marker to track early disease
progression and may serve as a tool to guide therapies in young
patients with CF.
Keywords: cystic fibrosis; disease progression; lung clearance
index; lung function
At a Glance Commentary
Scientific Knowledge on the Subject: Implementation of
intervention strategies to prevent lung damage early in cystic
fibrosis requires objective outcome measures that capture and
track lung disease.
What This Study Adds to the Field: In this study we
demonstrate that the Lung Clearance Index deteriorates in
preschool children with cystic fibrosis over time and during
episodes of cough and pulmonary exacerbations, whereas
similar symptoms in healthy children did not change the
Lung Clearance Index. These findings suggest that Lung
Clearance Index may be a useful marker to track early
disease progression and guide therapies in young patients
with cystic fibrosis.
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Cystic fibrosis (CF) lung disease begins early
in life and often progresses in the absence
of clinical signs and symptoms (1–6).
Consequently, there has been an
increasing emphasis on early intervention
strategies to prevent lung damage during
this critical period of disease progression,
for which objective outcome measures that
capture and track lung disease are needed.
Both imaging and functional tests have
been proposed as technologies applicable to
early lung disease, but these tools are largely
limited to the research setting.
One functional measure that is gaining
traction is the lung clearance index (LCI).
LCI is measured by the multiple breath
washout (MBW) test and quantifies the
efficiency with which gas mixes in the lungs.
A higher LCI value indicates greater
ventilation inhomogeneity and disease
severity. LCI is more sensitive than
spirometry in detecting lung function
abnormalities in patients with CF beyond
infancy (7, 8). The test requires only tidal
breathing and is therefore feasible to
perform in preschool (2–6 yr of age)
children (9). The LCI is responsive to
therapeutic interventions in the school-age
population and is being increasingly used
in interventional studies (7, 8). However,
the ability of LCI to monitor and track
clinical symptoms and disease progression
in patients with CF in early life is
unknown.
Longitudinal studies in older children
demonstrate that the LCI worsens with age
in school-age children with CF (10, 11).
LCI measured during preschool years has
been shown to predict both LCI and
spirometry outcomes at school age, a time
when most children with CF had abnormal
LCI values (12). These data further
emphasize the importance of the preschool
years as an opportunity for early
intervention in CF. However, these data
were limited to single measurements in the
preschool and school-age years, and
thereby are not representative of the utility
of lung function measurements in clinical
care, where tests are typically performed at
3-month intervals. Furthermore, although
parental reported cough at the preschool
visit was associated with higher LCI values
at school age, the study was not designed to
assess how changes in clinical status affect
the measurement. Preschool children often
experience respiratory symptoms triggered
by viral infections leading to challenges for
physicians to differentiate symptoms that
are disease related from those that also
occur in healthy children. Thus, current
treatment decisions in preschool children
with CF are mainly based on symptom
duration as a trigger for starting antibiotic
therapy rather than relying on objective
measures of pulmonary function.
To better define the utility of LCI in
preschoolers with CF, we designed a
longitudinal 12-month observational study in
preschool children. To differentiate disease-
related changes from those intrinsic to the
technique, the study included parallel
measurements in both healthy children and
children with CF. We chose study visits that
were not only representative of clinical care,
but also relevant for interventional studies so
that the information gained could be used in
both settings. The main aims of the study were
to (1) define the trajectory and variability of
LCI over time in health and disease, (2)
define clinical factors associated with
worsening of LCI during the preschool
years, and (3) define how LCI changes at
times of respiratory symptoms in healthy
preschool children and preschool children
with CF. Some of the results of these
studies have been previously reported in
the form of abstracts (13–18).
Methods
The study was designed as a multicenter
12-month longitudinal observational
study in preschool children. Children
between the ages of 2.5 and 6 years with
a confirmed diagnosis of CF, as well as
age-matched healthy control subjects were
enrolled at three North American CF
centers (Chapel Hill, Indianapolis, and
Toronto). Details of the inclusion and
exclusion criteria are presented in the
online supplement.
Participants attended study visits at
enrollment, 1 month (6 1 wk), 3 months
HC
78 Screened
72 Enrolled
CF
78 Screened
78 Enrolled
343 (84%) technically
acceptable MBW tests
410 (87.6%) MBW
tests analyzed
412 (88%) MBW tests
performed
(2 visits had
equipment
malfunction)
1 subject withdrew
from study (4 (<1%)
visits skipped)
52 (11%) visits skipped
due to schedule
conflicts
468 Visits expected
324 (83%) technically
acceptable MBW tests
389 (88.8%) MBW
tests analyzed
391 (89%) MBW tests
performed
(2 visits had
equipment
malfunction)
12 subjects withdrew
or were lost to follow-
up (30 (7%) visits
skipped)
17 (4%) visits skipped
due to schedule
conflicts
438 Visits expected
Figure 1. Summary of study population. Multiple breath washout tests were considered technically
acceptable according to quality control review criteria (31) and if there were at least two technically
acceptable trials in a test occasion. Percentages are calculated based on the total number of visits
expected (468 cystic fibrosis, 438 healthy control subjects), with the exception of the percentage
successful, which is calculated as number technically acceptable/number analyzed. CF = cystic
fibrosis subjects; HC = healthy control subjects; MBW=multiple breath washout.
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(6 2 wk), 6 months (6 2 wk), 9 months
(6 2 wk), and 12 months (6 2 wk). At each
visit a clinical examination, review of past
and current symptoms and treatments,
MBW, and spirometry were performed. All
children were free of acute respiratory
infection within 4 weeks of the enrollment
visit, whereas symptoms were recorded and
outcomes measured at all subsequent visits.
Visits were classified as stable, if no respiratory
symptoms were present. Respiratory
symptoms at the study visit included nasal
congestion and/or cough. In CF a
pulmonary exacerbation (PEx) was
defined as an increase in respiratory
symptoms (e.g., cough) and respiratory
symptoms combined with a physician-
based decision to treat with antibiotics
(either oral or intravenous). All PEx
events that occurred between consecutive
study visits were recorded.
MBW tests were performed with the
Exhalyzer D (EcoMedics AG, Duernten,
Switzerland), with adaptions for preschool
children (see online supplement).
Participants were enrolled if they could
complete a single MBW trial, whereas a
MBW test was considered successful if
there were at least two technically
acceptable trials. Spirometry was attempted
in all subjects according to American
Thoracic Society/European Respiratory
Society criteria (19).
Statistical Analysis
A generalized linear mixed-effects model
was used to distinguish changes in LCI
associated with normal growth and
development (i.e., healthy children) from
the progression of CF lung disease. Age was
used as the time-variable and an interaction
between disease status and age was used
to ascertain whether the rate of change in
LCI differed between health and CF. In a
similar analysis limited to CF, interactions
between time-independent patient factors
(sex, genotype, pancreatic status, history of
positive microbiology cultures) and age were
compared to assess whether the rate of
change in LCI differed between groups.
For time-dependent clinical measures
(anthropometry, symptoms, PEx), absolute
difference in LCI at a given age between
those with and without the characteristic
were assessed. Variability of the LCI was
characterized by the coefficient of variation
(CV%) and the intraclass correlation
coefficient (ICC). All statistical analyses
were performed in Stata Statistical Software,
Release 14 (StataCorp, College Station, TX).
Results
Study Population
One hundred and fifty-six preschool
children (78 healthy and 78 CF) were
recruited between January 2013 and June
2015, of which 150 were enrolled (72
healthy; 78 CF) (Figure 1). The average age
at enrollment was 4.1 years (range, 2.5–5.9).
The healthy children were well matched
for sex and age with the CF group, but
preschoolers with CF weighed less and were
shorter than healthy subjects (Table 1). Six
healthy children (8%) had a parental-
reported history of wheeze in the preceding
12 months, but did not report any other
symptoms or have a physician diagnosis
of asthma. Most CF participants were
diagnosed by newborn screening (79%). All
but three (96%) had class I-III mutations on
both alleles and 94% were pancreatic
insufficient. In the period between CF
diagnosis and the first study visit, 38%
(n = 30) had been hospitalized at least once
for respiratory causes. More than half of the
subjects had grown Staphylococcus aureus
(68%), Pseudomonas aeruginosa (60%), or
Haemophilus influenza (51%) at least once
in their life before enrollment. H. influenza
was more common in Canadian versus U.S.
participants (63% vs. 39%; P = 0.042),
whereas American participants were more
likely to have had methicillin-resistant
S. aureus (27% vs. 3%; P = 0.003).
Overall, 412 MBW measurements were
performed in preschool children with CF and
391 in healthy children. MBW testing was
successful for 66% of participants at the
Table 1. Characteristics of the Study Population at the Enrollment Visit
Demographics Healthy Controls (n = 78) CF (n = 78) P Values
Male, n (%) 37 (47.4) 39 (50.0) 0.749
White, n (%) 59 (75.6) 69 (88.5) 0.037
Age, mean (range) 4.0 (2.5 to 5.9) 4.3 (2.6 to 5.9) 0.097
Height-for-age centile, mean (range) 61.2 (6.7 to 99.8) 44.2 (0.8 to 97.5) 0.0002
Weight-for-age centile, mean (range) 62.6 (3.8 to 99.8) 43.1 (2.0 to 94.7) <0.0001
BMI-for-age centile, mean (range) 60.9 (1.31 to 99.9) 47.5 (0.99 to 94.9) 0.003
MBW enrollment visit
MBW attempted, n (%) 78 (100) 78 (100) 0.316
MBW successful, n (%) 52 (66.7) 51 (65.4) 0.599
LCI, mean (range), n = 103 (52 HC, 51 CF) 7.1 (6.1 to 8.1) 8.8 (6.4 to 13.6) <0.0001
Spirometry enrollment visit
Spirometry attempted, n (%) 71 (91.0) 74 (94.9) 0.348
Spirometry successful, n (%) 51 (71.8) 51 (68.9) 0.702
FEV0.75 % predicted, mean (range), n = 71
(27 HC, 44 CF)
96.9 (69.1 to 147.0) 90.9 (42.0 to 122.3) 0.125
FEV1 % predicted, mean (range), n = 89
(44 HC, 45 CF)
102.0 (73.3 to 136.4) 92.3 (42.5 to 119.3) 0.003
FEF25–75 % predicted, mean (range), n = 54
(25 HC, 29 CF)
96.7 (66.8 to 139.3) 94.0 (43.5 to 152.9) 0.687
zFEVt, mean (range), n = 94 (47 HC, 42 CF) 0.1 (22.4 to 3.3) 20.7 (24.3 to 1.8) 0.002
Definition of abbreviations: BMI = body mass index; CF = cystic fibrosis; FEF25–75% = forced expiratory flow, midexpiratory phase; FEV0.75 = forced
expiratory volume in 0.75 s; HC = healthy control subjects; LCI = Lung Clearance Index; MBW=multiple breath washout; zFEVt = z score for forced
expiratory volume in t seconds (where t represents either 0.75 or 1).
Values are bold if the difference between health and disease is significant at P, 0.05.
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screening visit and 89% of the follow-up visits;
further feasibility details are provided in the
online supplement. At enrollment LCI was
significantly elevated (worse) and FEV1 z scores
were significantly lower in the CF group
compared with the healthy control group
(Table 1). In healthy children, no relationship
between LCI and age at the first visit (see
Figure E1 in the online supplement) was noted;
therefore an age-independent upper limit of
normal was defined, and 67% of children with
CF had LCI above the upper limit of normal
(LCI of 8) at the first study visit.
The CF group had higher LCI values at
the first study visit compared with the healthy
group (Table 1). To understand the factors
Table 2. Factors Associated with LCI at the Enrollment Visit
Health CF
n
LCI units/year
(95% Confidence Interval) n
LCI units/year
(95% Confidence Interval)
First visit
Age 70 20.01 (20.11 to 0.10) 78 0.58 (0.13 to 1.03)
Height-for-age z score 70 0.05 (20.07 to 0.17) 78 20.39 (20.87 to 0.08)
Weight-for-age z score 70 0.02 (20.12 to 0.15) 78 20.31 (20.81 to 0.19)
BMI-for-age z score 70 20.02 (20.14 to 0.11) 78 0.02 (20.51 to 0.55)
Sex
Male 32 Reference 39 Reference
Female 38 20.10 (20.35 to 0.14) 39 0.12 (20.79 to 1.02)
Ethnicity
White 53 Reference 69 Reference
Other 17 20.10 (20.35 to 0.14) 9 20.85 (22.25 to 0.55)
Newborn screening
No 16 Reference
Yes 62 0.77 (20.34 to 1.87)
Mutation class
I–III 75 Reference
IV–V* 3 22.34 (24.63 to 20.05)
Pancreatic sufficient* 5 Reference
Pancreatic insufficient 73 1.14 (20.68 to 2.97)
Hospitalization history
0 hospitalizations 48 Reference
1 hospitalizations 13 0.92 (20.21 to 2.1)
2 hospitalization 10 1.9 (0.62 to 3.13)
31 hospitalization 7 2.6 (1.09 to 4.02)
Microbiology history
Pseudomonas aeruginosa 46 0.90 (0.00 to 1.79)
Staphylococcus aureus 54 1.44 (0.14 to 2.76)
Methicillin-resistant S. aureus 11 20.001 (21.30 to 1.30)
Stenotrophomonas maltophilia 16 0.31 (20.81 to 1.42)
Haemophilus influenzae 40 20.38 (21.29 to 0.51)
Burkholderia cepacia complex† 2 3.61 (0.87 to 6.35)
Aspergillus fumigatus 2 1.07 (21.78 to 3.92)
Treatment history
Hypertonic saline 34 0.69 (20.20 to 1.59)
Dornase alfa 29 0.52 (20.41 to 1.44)
Chronic inhaled antibiotic therapy 14 1.39 (0.26 to 2.52)
Definition of abbreviations: BMI = body mass index; CF = cystic fibrosis; LCI = Lung Clearance Index.
Coefficients are derived from a univariable linear regression analysis and represent the slope (LCI units/yr) (95% confidence interval). A positive coefficient
indicates higher (worse) LCI, whereas a negative coefficient represents lower (better) LCI. Values are bold if the estimate is significantly different from 0 at
the P, 0.05 significance level.
*Based on three observations in this category.
†Based on two observations in this category.
Table 3. Measures of Within-Subject and Between-Subject Variability of the Lung
Clearance Index Across the Six Study Visits Calculated as the CV (SD/Mean) and the
ICC (Proportion of the Variability Explained by the Variability Between-Subjects)
CV% Median (Range)
ICCWithin-Subject Within-Test Within-Subject Between-Test
Health 3.9 (0.3 to 12.3) 5.0 (1.5 to 20.1) 0.38
CF 4.9 (0.2 to 18.0) 9.4 (0.8 to 33.7) 0.57
CF stable visits only 4.9 (0.2 to 17.6) 7.2 (0.2 to 23.6) 0.71
Definition of abbreviations: CF = cystic fibrosis; CV = coefficient of variation; ICC = intraclass
correlation coefficient.
ORIGINAL ARTICLE
Stanojevic, Davis, Retsch-Bogart, et al.: LCI Progression in Preschool Children 1219
that are associated with higher LCI values at
the start of the study we conducted univariable
linear regression analysis in both health and
CF. In healthy children none of the
demographic characteristics were statistically
associated with LCI measured at the start of
the study (Table 2). In the CF group, LCI was
higher in older children, those with a history
of S. aureus, and in those with two or more
hospitalizations before the start of the study
(Table 2). In a multivariable analysis only
those with a history of hospitalizations (two
or more) had worse LCI values. In contrast,
none of the clinical variables were associated
with lower z scores for forced expiratory
volume in t seconds (FEVt) where t represents
either 0.75 or 1, in the CF participants at the
first study visit (see Table E1).
During the 12-month study period,
more than a third of participants (69%) were
culture positive for S. aureus, and 14% were
positive for P. aeruginosa infection; of
these, 10% had acquired P. aeruginosa for
the first time during the study period. The
proportion of participants receiving chronic
maintenance therapies during the study
period was similar to that observed before
the study; 50% were treated with hypertonic
saline, 42% with dornase alfa, and 23% with
chronic inhaled antibiotic therapy. One
participant was started on ivacaftor during
the study period.
Variability of LCI
In healthy participants the intra-test
repeatability (%CV) of the LCI was similar
to the inter-test reproducibility (Table 3).
These observations correspond to a small
ICC (0.38), which indicates that the
proportion of variance observed between
subjects is less than the variance observed
between repeated measurements in the
same subject.
In the CF group the inter-test %CV of
the LCI was greater than the intra-test %CV
(Table 3). The ICC in CF was larger than
that observed in health (0.57), and
increased when the analysis was limited to
stable visits (0.71). This suggests that part
of the within-subject variability of the LCI
may be explained by changes in symptoms
or clinical status of the participant. In
contrast, inter-test %CV for z scores for
FEVt (zFEVt) was 17% in healthy, and 42%
in CF, whereas the ICC for zFEVt was
much higher in healthy (ICC, 0.76), but
comparable in CF (all visits ICC, 0.58;
stable visits, ICC 0.64).
Progression of LCI
Overall throughout the 12-month study,
children with CF had higher LCI values
compared with healthy children (Figure 2).
Because children entered the study at
different ages, and older children had
higher LCI values at their first visit, we
investigated how LCI changed with age.
In healthy children LCI remained stable
with age (slope, 20.04 LCI units/yr; 95%
confidence interval [CI], 20.12 to 0.04;
P = 0.338) (Figure 3), whereas in CF the
LCI significantly deteriorated (slope, 0.40
LCI units/yr; 95% CI, 0.14 to 0.66; P =
0.003) (Figure 3). The rate of change of LCI
was significantly different between the
health and CF group (interaction term,
0.41; 95% CI, 0.12 to 0.70; P = 0.006). LCI
also deteriorated significantly when the
analyses were limited to asymptomatic
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Figure 2. Median lung clearance index values (interquartile range) for healthy control subjects (gray)
and cystic fibrosis subjects (black) at each of the six study visits. Lung clearance index was
significantly higher in the cystic fibrosis group compared with the healthy group at each visit.
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Figure 3. The average change in lung clearance index (LCI) in healthy control subjects (HC) and
cystic fibrosis subjects (CF). Slope (LCI units/yr) estimates were derived from an interaction term
between diagnosis group and age using a mixed-effects model with repeated measures of LCI where
random intercepts and random slopes were specified. The rate of deterioration of LCI in children with
cystic fibrosis was significantly different from that observed in health.
ORIGINAL ARTICLE
1220 American Journal of Respiratory and Critical Care Medicine Volume 195 Number 9 | May 1 2017
visits (slope, 0.34 LCI units/yr; 95% CI, 0.08
to 0.60; P = 0.011); this rate of change was
also statistically different from that
observed in healthy children (interaction
term, 0.38; 95% CI, 0.11 to 0.65; P = 0.007).
The rate of change was attenuated
when we limited the analysis to MBW
measurements before a PEx event (slope,
0.27 LCI units/yr; 95% CI, 20.01 to
0.56; P = 0.058), but was still significantly
different from the healthy group
(interaction term, 0.31; 95% CI, 0.04 to
0.58; P = 0.026). The deterioration of LCI
was independent of demographic and
clinical characteristics measured at the
start of the study. In other words, the rate
of deterioration (slope) was not modified
by events that occurred before the study,
even though these characteristics were
significantly associated with higher values
at the first visit (Table 2). In contrast to
LCI, the rate of change in FEVt z scores
was not different between health and CF
(Figure 4).
Factors Associated with Higher LCI
Values in Subjects with CF
CF participants with at least one positive
culture with S. aureus during the study
period had higher (worse) LCI values
compared with subjects that did not grow
S. aureus (Table 4). Similarly, subjects
treated with chronic inhaled antibiotics, a
proxy for chronic P. aeruginosa infection,
during the study period had higher (worse)
LCI values compared with those that
were not treated with chronic inhaled
antibiotics. In contrast, participants with
higher weight-for-age z scores had lower
(better) LCI values (i.e., for each unit increase
in higher the weight-for-age z score, the
LCI decreased by 0.41 LCI units (95% CI,
20.77 to 20.05).
For factors that changed over the study
period we evaluated whether absolute values
of LCI were elevated at a given age in
participants with a specific characteristic
compared with those without. Over the
12-month study period, 39 events with new
respiratory symptoms (nasal congestion,
cough, or both) were recorded in 28
healthy participants, and 133 events in 66
CF participants. Fifty-five (41%) of these
events in 41 CF participants were classified
as PEx treated with antibiotics; in 80% of
these events participants received oral
antibiotics. Study visit in children with
CF who had respiratory symptoms treated
with antibiotics (PEx) had LCI values that
were on average 1 unit higher (worse)
than those without PEx events (Table 4,
Figure 5). CF participants with cough that
was not treated with antibiotics also had a
significantly elevated LCI, albeit the effect
size was smaller than in those with PEx
(Table 4, Figure 5). In healthy participants
there was no effect of cough on LCI. Nasal
congestion was not associated with an
elevated LCI value in either the healthy
or CF groups (Figure 5).
The factors found to be significantly
associated with LCI in Table 4 (univariable
analysis) were then entered into a
multivariable analysis; only PEx (estimate,
0.96 LCI units/yr; 95% CI, 0.46 to 1.45)
and higher baseline LCI (estimate, 0.71 LCI
units/yr; 95% CI, 0.61 to 0.81) remained
significantly associated with a higher
LCI. In a separate analysis we also
evaluated whether LCI was predictive of
a PEx event at the next study visit. In a
mixed-effects logistic regression analysis,
which allowed each participant to have
multiple PEx events, the odds of a PEx event
were not explained by a participants’ LCI
value at the previous visit (odds ratio, 0.99;
95% CI, 0.84 to 1.16).
A similar analysis was conducted for
FEVt z scores (see online supplement). None
of the known risk factors for worse lung
function were significantly associated with
lower FEVt z scores at the start of the study
(see Table E1). Both upper and lower
airway symptoms were associated with
significantly lower FEVt z scores in
healthy and CF participants with no
significant differences between the groups
(Figure 6; see Table E2). Similar results
were observed for forced expiratory flow
(FEF)25–75% z scores; both cough and nasal
congestion were associated with lower
FEF25–75% z scores in health, whereas only
cough was associated with lower FEF25–75%
z scores in CF (data not shown).
Relationship between LCI and FEVt
At each study visit, the correlation between
LCI and zFEVt was low but statistically
significant (enrollment: r =20.30, P = 0.02;
1 mo: r =20.33, P = 0.01; 3 mo: r =20.51,
P, 0.001; 6 mo: r=20.59, P, 0.001; 9 mo:
r =20.51, P, 0.001; 12 mo: r =20.37,
P, 0.001). In most children with CF, there
was a discordance between LCI and zFEVt;
LCI values were above the upper limit of
HC
CF
2
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–1
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3 4
Age (years)
5 6
Figure 4. The average change in z score for forced expiratory volume in t seconds, where t is either
0.75 or 1 (zFEVt) in health and cystic fibrosis. Slope (zFEVt/yr) estimates were derived from an
interaction term between diagnosis group and age using a mixed-effects model with repeated
measures of zFEVt where random intercepts only were specified. Although the intercepts differed
between health and cystic fibrosis, the rate of decline in zFEVt was similar in both groups. CF = cystic
fibrosis subjects; HC = healthy control subjects.
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normal (“abnormal”) and zFEVt was above the
lower limit of normal (“normal”) (see Figure
E2). Overall, when the relationship between
LCI and zFEVt was modeled longitudinally,
there was a significant and inverse relationship
between LCI and zFEVt (slope, 20.67 LCI
units/FEVt z score; 95% CI, 20.85 to 20.49).
Discussion
This study characterizes clinical factors
associated with changes in lung function in
preschool children using repeated measures
performed at time points relevant for both
clinical care and interventional studies.
Although LCI and FEVt were equally
feasible, and discriminated between health
and disease at baseline, only the LCI
identified significant deterioration of
lung function in the CF population.
Furthermore, in this relatively young CF
population with mild lung disease, the LCI
was able to distinguish between participants
based on clinical symptoms. In contrast,
zFEVt was significantly lower for clinical
symptoms in both healthy and CF
participants. Specifically, the LCI was
significantly elevated during episodes of
cough and PEx events. Respiratory symptoms
in healthy children and symptoms of nasal
congestion in both health and CF were not
associated with higher LCI values,
suggesting that the LCI detects changes
reflecting worsening CF lung disease.
These data support the use of LCI as an
objective measure to track lung disease in
preschool children with CF.
Our findings further provide evidence
that PEx events in children (treated with
either oral or intravenous antibiotics) are
associated with deterioration in lung
function. A history of repeated early PEx
events, defined as hospitalizations for
respiratory causes, was associated with a
significantly elevated LCI at the start of the
study and PEx were associated with worse
LCI values. These findings are consistent with
several studies in older subjects that have
shown that PEx have negative consequences
for patients with CF (20, 21). Most studies
evaluating PEx have focused on events
treated with intravenous antibiotics, which is
not the treatment course for most events in
young children with CF. Our observations
support the clinical significance of pulmonary
symptoms treated with oral antibiotics, which
is consistent with previous findings that these
milder events have short- and long-term
impact on lung function (22, 23). A recently
published study linking changes in LCI
during a PEx event to changes in magnetic
resonance imaging outcomes suggest that LCI
may also be a sensitive outcome to assess
response to treatment for PEx events in
patients with CF (24). Although these data
are encouraging, the recovery after PEx
events will likely be heterogeneous with
some patients returning to baseline,
whereas others may not fully recover (25).
Further studies are needed to establish
whether LCI is suited to evaluate treatment
response during PEx in patients with CF.
Viral infections are common in
preschool children, which makes it difficult
to determine whether symptoms during
these events require treatment in patients
with CF. In this study we demonstrate for
the first time that upper respiratory
symptoms (i.e., nasal congestion) have no
impact on lung function as measured by LCI
in healthy children and in CF. In contrast,
although cough in healthy children was
not associated with higher LCI values, LCI
was elevated in children with CF with cough.
These findings suggest that increases in
LCI associated with pulmonary symptoms
are indicative of lower airway disease in
patients with CF. Cough is the most frequent
trigger for defining PEx in interventional
studies in this age group. Because this
Table 4. Factors Associated with LCI Values in Patients with CF
CF
[LCI units/year
(95% Confidence Interval)]
Time-independent factors
Baseline LCI 0.71 (0.62 to 0.80)
Hypertonic saline at enrollment
No Reference
Yes 0.18 (20.53 to 0.89)
Dornase alfa at enrollment
No Reference
Yes 20.09 (20.81 to 0.63)
Chronic inhaled antibiotics at enrollment
No Reference
Yes 0.99 (0.17 to 1.81)
Positive microbiology culture during the study
compared with reference group
(negative culture)
Pseudomonas aeruginosa 0.5 (20.7 to 1.7)
Staphylococcus aureus 0.8 (0.04 to 1.6)
Methicillin-resistant S. aureus 20.6 (21.2 to 0.9)
Stenotrophomonas maltophilia 20.4 (21.3 to 5.2)
Stenotrophomonas influenza 2.0 (21.1 to 5.2)
Burkholderia cepacia complex* 3.1 (0.002 to 6.2)
Aspergillus fumigatus 2.2 (20.8 to 5.2)
Time-dependent factors
Increasing height-for-age z score 20.23 (20.58 to 0.12)
Increasing weight-for-age z score -0.41 (20.77 to 20.05)
Increasing BMI-for-age z score 20.27 (20.59 to 0.06)
Symptoms
Pulmonary exacerbations
No Reference
Yes 1.05 (0.62 to 1.48)
Cough
No Reference
Yes 0.51 (0.13 to 0.89)
Nasal congestion
No Reference
Yes 0.12 (20.27 to 0.51)
Definition of abbreviations: BMI = body mass index; CF = cystic fibrosis; LCI = Lung Clearance Index.
Coefficients are derived from a univariable generalized mixed effects regression analysis and
represent the difference in LCI values (95% confidence interval) relative to the reference group. A
positive coefficient indicates higher (worse) LCI, whereas a negative coefficient represents lower
(better) LCI relative to the reference. Bold represents values that are significantly different from 0 at a
significance level of P, 0.05.
*Based on two observations in this category.
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symptom is rather nonspecific, thresholds
for duration of symptoms are also often
used in clinical practice and in clinical
trials (26). Our findings suggest that the
LCI may be a sensitive way to identify
patients who could benefit from treatment
during episodes of acute worsening of
respiratory symptoms.
In the current study clinical factors
known to be linked to greater disease
severity, such as infection with S. aureus
were associated with higher LCI values. Our
findings are consistent with those from a study
of younger patients with CF evaluated by
the AREST CF (Australian Respiratory Early
Surveillance Team for Cystic Fibrosis), which
reported higher LCI values in patients
whose bronchoalveolar lavage cultures were
positive for CF bacterial pathogens (27).
Although most of our cultures were from
upper respiratory samples (throat swabs),
which may not always reflect lower airway
infections (28), these findings nonetheless
support airway infection as a major driver of
lung disease progression in CF. A minimal
number of participants acquired new infections
during the observation period, thus the effect of
incident and new-onset infections on the LCI
could not be established in this study.
Our findings are consistent with
previous longitudinal studies that
demonstrate that LCI is a sensitive measure
of lung function and tracks with disease
progression. Even during our relatively short
observation period of 12 months the LCI
significantly worsened in a group of young
patients with CF. The natural rate of
deterioration of LCI observed in the current
study, both overall and in stable patients,
provides a baseline rate of change that can be
used to design interventional studies for this
age group. As more novel therapeutic
interventions become available that directly
target the dysfunctional CF transmembrane
conductance regulator, LCI may be a
functional parameter suitable to establish
whether CF transmembrane conductance
regulator modulators will impact lung
function trajectories over time in young
children where early intervention with
effective treatments could have the most
pronounced long-term effect.
The variability in LCI observed between
repeated measurements within the same
individual was quite heterogeneous and
lower than previously published studies (29).
In healthy subjects the ICC, a measure of the
variability of an outcome, was quite low,
indeed much lower than would be
expected of a test that is considered
reproducible and appropriate for tracking
disease progression (30). However, the
low ICC is likely biased by the narrow
range of LCI values observed in the
healthy children. The ICC in the CF
group was higher, and increased further
when the analyses were limited to stable
visits, which would suggest that part of
the within-subject variability of the LCI
can be explained by patient symptoms
and clinical status. Although this study
was designed to elucidate the sources of
the variability of the LCI, it remains
unclear whether the variability observed
during stable visits is an inherent
Upper Airway Symptoms
Cough
PEx
–2 –1.5 –1 –.5 0
Estimate
.5 1 1.5 2
Figure 5. Association between pulmonary symptoms and lung clearance index (LCI) in health (solid
line) and cystic fibrosis (CF) (dashed line). Estimates (absolute LCI during symptomatic visits relative to
asymptomatic visits) derived from a mixed-effects model of LCI, adjusted for age; symptoms were
treated as time-varying covariates. Neither upper airway symptoms nor cough were associated with
higher LCI values in healthy participants, whereas both cough and pulmonary exacerbation were
associated with significantly higher LCI values in CF (Table 4). Upper airways symptoms were not
associated with higher LCI values in CF. PEx = pulmonary exacerbation.
Upper Airway Symptoms
Cough
PEx
–2 –1.5 –1 –.5 0
Estimate
.5 1 1.5 2
Figure 6. Association between pulmonary symptoms and z scores for the forced expiratory volume in t
seconds, where t is either 0.75 or 1 (zFEVt) in health (solid line) and cystic fibrosis (dashed line). Estimates
(absolute zFEVt during symptomatic visits relative to asymptomatic visits) derived from a mixed-effects
model of lung clearance index, adjusted for age; symptoms were treated as time-varying covariates. Visits
when both healthy and patients with cystic fibrosis had both upper and lower airway symptoms had
significantly lower zFEVt values, as did pulmonary exacerbation visits. PEx = pulmonary exacerbation.
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physiologic property of the test (i.e.,
the ventilation distribution of the
lungs is more inhomogeneous in CF
compared with health), or if the test is
detecting abnormalities in the lung not
associated with symptoms. Concurrent
measurements of LCI and other sensitive
measures of structural lung disease, such
as high-resolution computed tomography
or magnetic resonance imaging, will help
to further elucidate the mechanisms that
drive the variability of the LCI.
Strengths and Limitations
The study was designed to include
repeated measurements of LCI at time
points frequently used for interventional
studies and to mimic quarterly clinic
visits. Thus, the LCI changes observed
over the 12-month study period reflect
changes expected in a real-life setting.
We applied a mixed-effect model that allows
for a varying number of study visits and
intervals between visits to maximize the
available data for each subject. The lack of
association with zFEVt may have been biased
for several reasons. Spirometry was not a
primary outcome and if children were tired
after MBW testing, spirometry was not
measured. In addition the healthy group had
lower z scores than expected suggesting that
the Global Lung Function Initiative may not
fit this population.
Symptoms and PEx events that
occurred between study visits were
captured, and outcomes were measured
regardless of symptoms. Although this
approach gave a complete account of
significant pulmonary events during the
study period, the magnitude of change
in LCI for a PEx event may have been
underestimated. At the extreme, the PEx
could have occurred 3 months before
the study visit, thus the measured LCI
may not have reflected the PEx events.
Furthermore, a PEx event was defined
based on a physicians’ decision to treat
symptoms (i.e., cough). The symptoms
that led the physician to treat the
symptoms may be independently
associated with LCI and our estimate of
the effect of PEx may be biased. Finally, all
of the outcomes were limited to functional
pulmonary function tests, and did not include
objective imaging studies that measure
structural lung damage (e.g., high-
resolution computed tomography,
magnetic resonance imaging). Future
studies that capture repeated baseline
measurements of LCI, and measures
at the onset of symptoms and the end
of treatment, will be necessary
to more accurately define thresholds for
changes in LCI that would benefit from
treatment.
Conclusions
The LCI demonstrates progression of lung
disease in preschool children with CF and
corresponds to changes in lower airway
symptoms in children with CF. LCI may be
a useful marker to track early disease
progression and may serve as an endpoint
to guide therapies in young patients
with CF. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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